FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for DYMISTA (azelastine hydrochloride and fluticasone propionate) from Viatris Specialty LLC, under NDA202236.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• DYMISTA (azelastine hydrochloride and fluticasone propionate)

Snippet

SUPPL AP for DYMISTA (AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE)